Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

HEALTHCARE (NY:XLV)

135.28 -7.85 (-5.48%)
Official Closing Price Updated: 8:00 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about HEALTHCARE

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
28 29 Next >
Bearish Vision As Apple Tests All-Time High
Apple's first new product category in 8 years is a mixed-reality headset for $3499. 
Via Talk Markets
Market Mixes It Up With A Broad Rally
Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive. 
Via Talk Markets
Corporate Bankruptcies At Levels Last Seen During The Pandemic
Despite all of the mainstream talk about a strong, resilient economy, corporate bankruptcies through the first four months of 2023 came in at the highest level since 2010. 
Via Talk Markets
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?
A steady rotation out of biotech and healthcare stocks into the Nasdaq-100 large-cap tech stocks can be unnerving for portfolio managers. 
Via Talk Markets
Tech In Orbit
Tech has led the way higher with a sharp move this week. The sector is now extremely overbought, trading 3.23 standard deviations above its 50-DMA; the fifth most overbought reading on record. 
Via Talk Markets
A Good Week For The Market But A Pause In The Biotech Rally
Healthcare stocks have been lagging in 2023 with the XLV down 1.97% MTD and 3.34% YTD with CVS and UNH contributing to the weakness. 
Via Talk Markets
Your Mid-May Market Update: Sector Strength And Weakness So Far In 2023
Today's session continued the ongoing theme of 
Via Talk Markets
Good Odds And Odd Goods
Investing is all about making money. It is the realm where you go find out where the odds are good, even if the goods are odd. 
Via Talk Markets
5 Most-Loved ETFs Of Last Week
Last week was marked by volatility. Overall, ETFs pulled in a modest $260 million in capital for the week, bringing total inflows of $111.7 billion year to date. 
Via Talk Markets
Something Happened In Biotech Last Week
Biotech stocks were more constructive last week with some sharp moves up. 
Via Talk Markets
Seasonal Mid Point
The next three months, which is the period straddling the back half of spring and the first half of summer, has been relatively strong in the last ten years. 
Via Talk Markets
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo. 
Via MarketBeat
6 Best Healthcare Stocks to Buy Right Now
Whether you invest in healthcare stocks for pharmaceuticals, medical devices or health insurance, the opportunities are limitless. Learn more with MarketBeat. 
Via MarketBeat
Topics Economy Intellectual Property
Exposures Economy Intellectual Property Product Safety
Healthcare Sector Update: MedTech Trending Up
Earnings from major device companies and large-cap biopharma over the next two weeks will help us ascertain risks for the market. 
Via Talk Markets
Healthcare Innovation Drives Medical Device Makers To New Highs
Medical products makers Stryker and Boston Scientific are rallying to all-time highs, while sector peer DexCom is forming a constructive base. 
Via MarketBeat
Tuesday Talk: Eggs Still In The Basket
Investors returned to the market Monday, after the Good Friday trading holiday, with most of their eggs still intact. The early Spring rally seems to be holding as the market prepares for Q1 banking... 
Via Talk Markets
April Is Busting Out For Healthcare And Biotech
Last week was a good week for healthcare stocks and most large cap biopharmaceutical stocks resumed an upward trend. 
Via Talk Markets
Weekly Market Pulse: History Lessons
Studying the past doesn’t somehow allow us to predict the future. But it does tell us that there is a range of potential outcomes and we should be reluctant to make big changes to our portfolios based... 
Via Talk Markets
GILD - Chart Of The Week
The daily chart looks pretty strong right now. The stock is trying to break through the resistance line that started around the beginning of December. 
Via Talk Markets
Recession Playbook In Action: Cooling Labor Market Triggers Rally In Treasuries, Gold; Stocks Decline
Recent economic data has prompted investors to hedge against the rising likelihood of a recession.  In February 2023, there were 9.9 million job openings, which was the lowest level since May 2021 and... 
Via Benzinga
Large Cap Biopharmaceuticals Q1 2023: In This Bullish Run Biotech Lags
It was very difficult to make money in Q1 trading healthcare or biotech ETFs because of the sharp rally in other sectors. Nonetheless, there were two big winners. 
Via Talk Markets
Financials And Tech Continue To Split: Your Sector Trade Ideas For The Week Ahead
Current trade opportunities for Financials and Tech along with other sectors setting up trade logic. 
Via Talk Markets
Energy & Financials Lead, But The Flight To Quality Has Begun
It's easy to get suckered into thinking the crisis is over and buy the most oversold stocks. For financials, this comes with significant risk as the 
Via Talk Markets
Can Healthcare Stocks Survive Macro Headwinds?
Healthcare stocks are supposed to be defensive plays in a choppy market. However, over the past 18 months, the XLV is flat and down 6% over one year. 
Via Talk Markets
Sector Performance Experiences A Historical Divergence
The first quarter of 2023 is coming to a close next week, and checking in on year-to-date performance, there has been a big divergence between the winners and losers. 
Via Talk Markets
Small Cap Biotechs Slammed By SVB Collapse
Nothing like a banking crisis to start off a weekend. But maybe by the end of this upcoming week of turmoil we'll worry less about inflation. 
Via Talk Markets
FDA Seeks 10% Increase In Biden's FY 2024 Budget, Proposes Enhancing Regulatory Authorities
Via Benzinga
U.S. Weekly Fund-Flows Insight Report: Investors Embrace Both Fixed Income And Equity ETFs
As investors appeared to ignore rising Treasury yields, stocks generally managed to remain on the plus-side for the fund-flows week. 
Via Talk Markets
Covis Pharma To Withdraw Only FDA-Approved Treatment To Prevent Preterm Births
Via Benzinga
Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
28 29 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.